Skip to main content
Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.

Publisher: Bentham Science Publishers

More about this publication?
Volume 5, Number 3, 2009

Articles

Inhibition of Disulfide Reductases as a Therapeutic Strategy
pp. 117-133(17)
Authors: Kaakoush, Nadeem O.; Mendz, George L.

Favourites:
ADD

Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
pp. 134-147(14)
Authors: Watermeyer, Jean M.; Kroger, Wendy L.; Sturrock, Edward D.; Ehlers, Mario R.W.

Favourites:
ADD

Diacylglycerol Kinase Inhibition and Vascular Function
pp. 148-152(5)
Authors: Choi, Hyehun; Allahdadi, Kyan J.; Tostes, Rita C.A.; Webb, R. C.

Favourites:
ADD

Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy
pp. 153-162(10)
Authors: Mehta, Payal; Butchar, Jonathan P.; Tridandapani, Susheela

Favourites:
ADD

Competitive Parabolic Inhibition of Rat Tissue Kallikrein by Aprotinin
pp. 163-170(8)
Authors: Diniz, Carolina M.; Xavier, Luciana P.; Santoro, Marcelo M.; Figueiredo, Amintas F.S.

Favourites:
ADD

Fixed Dose Combination of Ceftazidime Plus Tobramycin Acts as Free Radical Scavenger in Liver of Mus musculus Mice
pp. 171-175(5)
Authors: Dwivedi, V. K.; Soni, A.; Chaudhary, M.; Sehgal, R.; Shrivastava, S. M.

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content